SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending after announcing record-high vehicle deliveries for December and the fourth quarter, significantly surpassing previous figures and nearing one million cumulative vehicles. This strong performance, further supported by extended EV subsidies in China, is driving considerable community discussion and optimism about the company's path to profitability and its competitive standing in the electric vehicle market.

Intelligent Bio Solutions, Inc. is a medical technology company, which engages in delivering testing solutions. It operates through the Intelligent Fingerprinting Products (IFPG) and Saliva Glucose Biosensor Platform (SGBP) segments. It offers biochemistry, immunology, tumor markers, hormones, and nucleic acid diagnostic modalities. The company was founded on December 5, 2016 and is headquartered in New York, NY.

Intelligent Bio Solutions Inc

Intelligent Bio Solutions Inc. is trending following news of a strategic manufacturing partnership set to scale production of its drug screening reader for anticipated U.S. market entry. The community is actively discussing the stock's massive volume and micro-float, fueling excitement for potential short-squeeze-like parabolic gains. However, a recent private placement with lower-priced warrants has sparked debate among traders, creating a highly volatile environment with divided opinions on its immediate future.

Tidal Trust II - Defiance Daily Target 2x Long SMCI ETF

Defiance Daily Target 2X Long SMCI ETF

SMCX is currently trending amidst significant investor confusion and frustration surrounding a recent dividend event and persistent tracking discrepancies with its underlying asset, SMCI. The community is actively questioning the ETF's unusual behavior, with some alleging it's a "scam" or facing an imminent reverse split, while others view the current downturn as a potential buying opportunity despite concerns about leveraged product decay.

Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. Its products include LUNAR-COV19, LUNAR-FLU, LUNAR-OTC, and LUNAR-CF. The company was founded in 2013 and is headquartered in San Diego, CA.

Arcturus Therapeutics Holdings Inc

Arcturus Therapeutics is currently a hot topic, with community discussion centering on the ongoing delay and mixed initial data for its inhaled cystic fibrosis therapy, ARCT-032, which showed some mucus plug reduction but not significant lung function improvements. Investors are closely monitoring an active trade secret lawsuit against AbbVie, generating widespread hope for a substantial settlement or potential acquisition. Many believe the company's advanced mRNA platform and solid cash runway make the stock deeply undervalued amidst significant short interest.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending after a recent price surge ignited a polarized community discussion. Supporters emphasize its real-world utility through Flexa's merchant network and anticipate significant growth with pending regulatory clarity and strategic partnerships. However, many investors express deep frustration, warning of sustained manipulation and a history of pump-and-dump cycles despite its technological foundations.

SpaceX engineers reusable launch vehicles and the Starlink satellite constellation for global broadband. Their focus on rapid reusability and vertical integration drives down launch costs and accelerates space access.

SpaceX PreStocks

SpaceX is trending due to widespread anticipation of a potential IPO in 2026, which is igniting significant speculative interest across the broader aerospace sector. Community discussions are heavily focused on identifying "SpaceX IPO plays," with companies like Momentus ($MNTS) gaining traction for its partnership on Falcon 9 missions and a notably low share count, sparking comparisons to past explosive meme stock surges.

Grayscale Investments LLC - Grayscale Bitcoin Trust

Grayscale Bitcoin Trust

Grayscale Bitcoin Trust (GBTC) is trending amidst a fervent debate over Bitcoin's near-term price direction, with discussions highlighting recent ETF outflows and broader market dynamics. The community remains sharply divided, as many anticipate a "parabolic" rally for Bitcoin as a hedge against inflation, while others warn of an impending "crypto winter" and significant price corrections based on historical cycles and perceived lack of intrinsic value.

Zevra Therapeutics, Inc. is a commercial-stage rare disease company that combines science, data and patient needs to create therapies for diseases with limited or no treatment options. The firm focuses on the treatment of rare neurological and sleep conditions such as certain Urea Cycle Disorders, Niemann Pick Disease Type C and Idiopathic Hypersomnia. The company receives royalties for AZSTARYS from its commercial partner Corium. The company was founded by Christal M. M. Mickle and Travis C. Mickle on October 30, 2006 and is headquartered in Celebration, FL.

Zevra Therapeutics Inc

Zevra Therapeutics is trending amid intense community discussion following recent developments, including a partial summary judgment in its ongoing litigation and strategic changes to its executive team, which are fueling heightened speculation around a potential acquisition. Investors are closely monitoring progress for its rare disease therapy, MIPLYFFA, toward European market access and a patent term extension, while broadly criticizing management for perceived undervaluation and executive compensation. Despite these concerns, many maintain a bullish outlook, citing the company's significant cash reserves and pipeline assets as indicators of untapped value.

iShares Ethereum Trust (The) - Undivided Beneficial Interest

iShares Ethereum Trust ETF

iShares Ethereum Trust ETF ($ETHA) is trending amidst strong speculation surrounding spot Ethereum ETF approvals, particularly those offering staking, which is expected to drive institutional demand. The recent "Fusaka Upgrade" is also a key talking point, with its impact on Ethereum's burn rate fueling bullish outlooks and active options trading. While many investors are actively 'buying the dip' and positioning for a potential decoupling from Bitcoin, others maintain caution regarding crypto market volatility.

Viridian Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development of proprietary RNA-targeted therapeutics. Its product candidates include Cobomarsen, which treats patients with certain cancers, including cutaneous T-cell lymphoma and adult T-cell leukemia/lymphoma, and Remlarsen and MRG-229, which are made for the treatment of patients with pathological fibrosis. The company was founded by William S. Marshall and Bruce L. Booth in February 2006 and is headquartered in Waltham, MA.

Viridian Therapeutics Inc

Viridian Therapeutics is generating significant buzz after the FDA accepted its Biologics License Application for Veligrotug, granting Priority Review for Thyroid Eye Disease and setting a PDUFA target. The community is widely discussing Veligrotug's potential as a best-in-class treatment, citing its strong efficacy across both active and chronic TED compared to current therapies, which fuels analyst upgrades and M&A speculation for the company's innovative pipeline.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

VOO Fundamental Analysis

Below is Validea's ETF fundamental report for Vanguard S&P 500 ETF (VOO). The report looks at VOO's exposure to the major investing factors including value, quality, momentum and low volatility...

 Michael Burry attends "The Big Short" New York screening Ziegfeld Theater on November 23, 2015 in New York City. 

'Big Short' Investor Michael Burry Says He Is Not Short Tesla Even As He Calls The Stock ‘Ridiculously Overvalued’

The investor and hedge fund manager clarified in an X post reply that he is not short Tesla shares. 

Equity

The investor and hedge fund manager clarified in an X post reply that he is not short Tesla shares. 


Tesla Cybercab or Robotaxi two-passenger battery-electric self-driving car on display at the AutoSalon on January 10, 2025 in Brussels, Belgium. (Photo by Sjoerd van der Wal/Getty Images)

Tesla Starts Cybercab Production Ahead Of Launch In 2026

The Cybercab is a dedicated robotaxi offering with no pedals, steering wheel or side view mirrors.

 6 ETF Predictions for 2026

2026 could favor SPY, SLV, KBWB, TAN & global ETFs as AI, metals, banks and clean energy shape the next leg of market gains.

<ul class="summary-bullets"><li>According to Rosenblatt, the acquisition represents a natural synergy for Meta as it continues to grow its small-business AI capabilities.</li><li>The deal is viewed as “potentially transformative” for the company, akin to Meta’s purchases of Instagram in 2012 and WhatsApp in 2014.</li><li>According to a Bloomberg report, the deal is valued at about $2 billion.&nbsp;</li></ul>Meta Platforms Inc.’s (META) Manus acquisition aligns with its expansion strategy in the WhatsApp small business ecosystem and complements CEO Mark Zuckerberg's vision for personal AI integration, said Rosenblatt.On Monday, the tech giant announced it has&nbsp;agreed to acquire Singapore-based tech startup Manus for an undisclosed sum.<h2 class="st-heading-2">Strategic Fit</h2>According to Rosenblatt, the acquisition represents a natural synergy for Meta as it continues to grow its small-business AI capabilities. The deal is viewed as “potentially transformative” for the company, akin to Meta’s landmark purchases of Instagram in 2012 and WhatsApp in 2014.The firm noted that Manus’ agentic AI technology can enhance Meta’s offerings for small and medium-sized enterprises (SMBs), improving automation and AI-driven customer engagement.&nbsp;<a href="https://stocktwits.com/symbol/META">Meta Platforms’ stock</a> inched 0.1% higher in Tuesday’s premarket. However, on Stocktwits, retail sentiment around the stock remained in ‘extremely bearish’ territory amid ‘low’ message volume levels.&nbsp;<figure class="image"><img style="aspect-ratio:932/95;" src="https://news.stocktwits-cdn.com/Screenshot_2025_12_30_100632_png_7b6b705aba.webp" alt="META’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Dec. 30, 2025 | Source: Stocktwits" width="932" height="95"><figcaption>META’s Sentiment Meter and Message Volume as of 09:40 a.m. ET on Dec. 30, 2025 | Source: Stocktwits</figcaption></figure><h2 class="st-heading-2">Meta’s AI Strategy</h2>According to a Bloomberg<a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-29/meta-acquires-startup-manus-to-bolster-ai-business"> report</a>, Meta has struck a deal to acquire Manus, as part of its push to turn its heavy spending on artificial intelligence into a major business. The report pegged the deal value at about $2 billion.&nbsp;The purchase stands out as an uncommon U.S. takeover of an Asian technology firm, as Manus is a AI agent company based in Singapore.&nbsp;In 2025, Meta undertook a multibillion-dollar hiring spree, bringing in top AI talent, including Alexandr Wang, founder of Scale AI, and other industry veterans like Nat Friedman and Shengjia Zhao. In November, the company announced a $600 billion investment to expand AI data centers, and enhance technology capabilities.&nbsp;META stock has gained over 13% year-to-date.&nbsp;Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/michael-steinberger-book-on-alex-karp-gets-the-internet-talking/cL7IctKREU6">Michael Steinberger’s Book On Alex Karp Gets The Internet Talking – Here’s More On ‘The Philosopher In The Valley’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In Créteil, France, on September 29, 2025, the Meta AI logo appears on a smartphone.

Meta’s Strategic Move With Manus Could Mirror Instagram, WhatsApp Wins, Says Rosenblatt

The firm noted that Manus’ agentic AI technology can enhance Meta’s offerings for small and medium-sized enterprises.

<ul class="summary-bullets"><li>L&amp;F Co. was contracted to supply Tesla with high-nickel cathode material which was to be used in Cybertruck batteries.</li><li>However, only small amounts were provided due to delays in the vehicle’s development and low consumer demand, a person familiar with the matter told Bloomberg.&nbsp;</li><li>L&amp;F said in a statement to Bloomberg that the revision was inevitable in light of changes in the global electric vehicle market and battery supply conditions.</li></ul> Tesla Inc’s (TSLA) South Korean supplier L&amp;F Co. has reportedly slashed its supply contract with the EV maker down to 9.73 million won from 3.83 trillion won.Bloomberg <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-12-29/tesla-cybertruck-flop-proves-costly-for-south-korean-supplier">reported</a> on Monday, citing a filing, that the company slashed the contract first announced in February 2023, citing a change in supply quantity. The report also noted a person familiar with the matter attributing the slash in part to issues with the Cybertruck. The supplier only ended up providing a tiny fraction of battery material that the carmaker had ordered nearly three years ago, they added. &nbsp;The Tesla Cybertruck is among the company’s pricier offerings with a starting price of $79,990. Its more premium Cyberbeast model has a starting price of $114,990.<h2 class="st-heading-2">The Slashed Contract</h2>L&amp;F was contracted to supply Tesla with high-nickel cathode material which was to be used in Cybertruck batteries but only small amounts were provided due to delays in the vehicle’s development and low consumer demand, a person familiar with the matter told Bloomberg.The supply contract was also affected by broader policy and economic issues, including the elimination of Inflation Reduction Act subsidies which included a $7500 federal tax credit on the purchase of select EVs, the person added.L&amp;F said in a statement to Bloomberg that the revision was inevitable in light of changes in the global electric vehicle market and battery supply conditions.<h2 class="st-heading-2">Weak Demand Haunts The Stainless Steel Juggernaut</h2>Tesla started delivering the Cybertruck in November 2023 after a long wait. However, the truck was pricier than proposed during unveiling in 2019, dragging down demand and preventing reservation holders from actually placing the order. Musk had said in 2019 that the entry level variant of the truck would start at just about $40,000, while the most premium version would start at around $70,000.The Cybertruck’s stainless steel exterior and angular design also pulled split opinions, with some deeming it ugly while others appreciated the change.Musk has previously predicted that Tesla could sell up 500,000 Cybertrucks annually. However, in 2024, the company sold only 85,133 units of all its premium models combined, which includes the Model S, X and the Cybertruck, putting Cybertruck annual sales alone at below 30,000 units on an estimate.<h2 class="st-heading-2">How Did Stocktwits Users React?</h2>On Stocktwits, retail sentiment around TSLA stayed within the ‘bearish’ territory while message volume fell from ‘high’ to ‘normal’ levels.A Stocktwits user, however, reiterated their long term bullish stance on Tesla, highlighting possible upsides from the company’s autonomous driving efforts and dedicated robotaxi offering called the Cybercab.<stembedurl>https://www.stocktwits.com/Wiseman8/message/640331707</stembedurl><a href="https://stocktwits.com/symbol/TSLA">TSLA stock</a> has gained 15% this year and by about 11% over the past 12 months.Also See: <a href="https://stocktwits.com/news-articles/markets/equity/sellas-life-sciences-group-stock-soars-as-it-nears-final-analysis-in-cancer-study/cL7dROARExt">SELLAS Life Sciences Group Stock Soars As It Nears Final Analysis In Cancer Study</a>For updates and corrections, email newsroom[at]stocktwits[dot]comExchange Rate: 1 WON= 0.0007 USD

The sun rises on a Tesla Cybertruck as it drives next to the Hudson River on October 31, 2024, in Weehawken, New Jersey. (Photo by Gary Hershorn/Getty Images)

Tesla Supplier Reportedly Slashes Contract In Part Due To Lower-Than-Expected Cybertruck Demand

Bloomberg reported on Monday, citing a filing, that the supplier slashed the contract first announced in February 2023, citing a change in supply quantity.

Will the Ongoing Market Rally Continue in 2026? ETFs in Focus

S&P 500 momentum and retail inflows set the stage for a potential 2026 rally, with ETFs offering ways to ride the bullish trend.

1 Vanguard Index Fund Could Turn $375 per Month Into a $798,600 Portfolio That Pays $13,500 in Annual Dividend Income

Key PointsHistory says investing $375 per month in the Vanguard S&P 500 ETF can build a $798,600 portfolio that pays $13,500 in annual dividend income in three decades...

Top-Performing International ETFs of 2025

International ETFs like VEA, EZU & EEM outshone U.S. peers in 2025 as cheaper valuations, diversified exposure, and stimulus measures drove substantial gains.

The Biggest ETF Stories of 2025 and the 2026 Outlook

Bloomberg's Eric Balchunas breaks down ETFs' record-breaking 2025 and what lies ahead.

VOO
Vanguard S&P 500 ETF

Feed

News

Sentiment

Fundamentals

Info

Latest VOO News

VOOVanguard S&P 500 ETF